Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2027

Conditions

Pancreatic CancerAdjuvant Therapy

Interventions

DRUG

Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy

Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines

Trial Locations (1)

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

lead

Sichuan University

OTHER